Drug Profile
ISS-peanut allergen conjugate - Dynavax
Alternative Names: Ara h 2-ISS allergen conjugateLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class Allergens; Antiallergics; Food allergy immunotherapies; Glycoproteins; Oligonucleotides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Peanut hypersensitivity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Peanut-hypersensitivity in USA
- 20 Jul 2007 This programme is still in active development
- 22 Mar 2005 Dynavax Technologies and UCB have terminated their development and commercialisation collaboration in seasonal allergy products worldwide